This severe competitive disadvantage (Figure 7F) supports the hypothesis that BIRC5 is a specific genetic dependency of DNMT3A-mutant T-ALL and targeting BIRC5 in this subset of patients may be an effective precision medicine strategy. This evidence concerns the gene BIRC5 and acute lymphoblastic leukemia.